A Phase 4 interventional study of AI-1000 G2 and Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-19.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 58th largest by enrollment, is one of 4 that started in 2016, is one of 32 in phase 4, and was the 91st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 86th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 28 in phase 4, and was the 205th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD). The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2. Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
Device: AI-1000 G2 · Drug: Tocilizumab
HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
Device: AI-1000 G2 · Drug: Tocilizumab
Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
Device: AI-1000 G2 · Drug: Tocilizumab
CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
Device: AI-1000 G2 · Drug: Tocilizumab
HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
Device: AI-1000 G2 · Drug: Tocilizumab
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Also known as: Actemra/RoActemra, RO4877533
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the first unassisted use (Day 14) was reported.
Time frame: Day 14
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the second unassisted use (Day 28) was reported.
Time frame: Day 28
Percentage of Participants Who Successfully Performed Ancillary Tasks During First and Second Unassisted Use
Ancillary tasks included those tasks where the potential harm resulting from use error would be minor in severity, or the resultant harms were estimated to occur at sufficiently low levels. Ancillary tasks included the following: wash hands; clean the injection site with alcohol swab; wait for the alcohol to dry; dispose of the autoinjector cap; inspect full dose delivered after use; dispose of the autoinjector; and treatment of injection site after injection. The percentage of participants who succesffully performed ancillary tasks during the first (Day 14) and second unassisted use (Day 28) was reported.
Time frame: Days 14, 28
Visual Analog Scale (VAS) Score for Injection Pain Among Participants With RA
Injection pain was assessed on a continuous 100-millimeter (mm) VAS, where 0 mm represents "no pain" and 100 mm represents "unbearable pain". The mean VAS response at each assessment timepoint was reported among participants with RA.
Time frame: 0 and 15 minutes after injection on Days 0, 14, 28
Percentage of Participants by Response to Categorical Scale of Injection Pain Among Participants With RA
Injection pain was assessed on a categorical 6-point Likert scale, ranging from "no pain" to "severe and intolerable". The percentage of participants was reported by response at each assessment timepoint among participants with RA.
Time frame: 0 and 15 minutes after injection on Days 0, 14, 28
Percentage of Participants by Response to Device Satisfaction Questionnaire
Device satisfaction was assessed using twelve questions on a categorical 5-point Likert scale, ranging from "strongly agree" to "strongly disagree". Question (Q) 1 (felt the autoinjection was easy to use), Q2 (felt comfortable while using the autoinjector), Q3 (felt the autoinjector was easy to hold), Q4 (able to tell when injection had completed), Q5 (felt he/she can inject properly with the autoinjector), Q6 (felt he/she had control over the injection process), Q7 (felt confident that he/she injected successfully), Q8 (felt it is easy to dispose of the autoinjector), Q9 (autoinjector would help to manage his/her injection schedule), Q10 (liked the look/feel of the autoinjector), Q11 (would recommend the autoinjector to someone else who needed to inject), Q12 (would continue having injections with the autoinjector). The percentage of participants was reported by response at each assessment among participants with RA, CGs, and HCPs.
Time frame: Days 0, 14, 28
Tender Joint Count (TJC) Among Participants With RA
Sixty-eight joints were assessed for tenderness among participants with RA. The number of tender joints at Baseline was reported.
Time frame: Baseline (Day 0)
Swollen Joint Count (SJC) Among Participants With RA
Sixty-six joints were assessed for swelling among participants with RA. The number of swollen joints at Baseline was reported.
Time frame: Baseline (Day 0)
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Among Participants With RA
Ability to perform daily living activities was assessed across eight component sets including dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Twenty questions were scored on a 4-point Likert scale from 0 meaning "without any difficulty" to 3 meaning "unable to do". The overall score was computed as the sum of domain scores divided by the number of domains answered. Therefore, the score range for HAQ-DI was the same as that of the individual questions, that is, from 0 to 3, where 0 indicates "least difficulty" and 3 indicates "extreme difficulty". The mean change from baseline in HAQ-DI at each assessment was reported among participants with RA.
Time frame: Days 0, 14, 28
| Milestone | Caregivers | Healthcare Professionals | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|---|---|
| Started | 17 | 19 | 19 | 17 | 19 |
| Safety population | 17 | 19 | 18 | 17 | 19 |
| Completed | 17 | 18 | 18 | 16 | 18 |
| Not completed | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the first unassisted use (Day 14) was reported.
| percentage of participants | RA Group 1 (Self-Administration) | Caregivers | Healthcare Professionals |
|---|---|---|---|
| Open carton, remove device/documents | 100.00 | 100.00 | 100.00 |
| Remove cap | 100.00 | 100.00 | 100.00 |
| Start injection | 93.75 | 94.12 | 100.00 |
| Hold until complete dose delivered | 100.00 | 100.00 | 100.00 |
| Release activation button | 100.00 | 100.00 | 100.00 |
| Check expiry date | 88.24 | 58.82 | 72.22 |
| Inspect device prior to use | 76.47 | 47.06 | 66.67 |
| Inspect medication prior to use | 82.35 | 82.35 | 88.89 |
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the second unassisted use (Day 28) was reported.
| percentage of participants | RA Group 1 (Self-Administration) | Caregivers | Healthcare Professionals |
|---|---|---|---|
| Open carton, remove device/documents | 100.00 | 100.00 | 100.00 |
| Remove cap | 100.00 | 100.00 | 100.00 |
| Start injection | 100.00 | 100.00 | 100.00 |
| Hold until complete dose delivered | 100.00 | 100.00 | 100.00 |
| Release activation button | 100.00 | 100.00 | 100.00 |
| Check expiry date | 94.44 | 76.47 | 94.44 |
| Inspect device prior to use | 77.78 | 58.82 | 83.33 |
| Inspect medication prior to use | 88.89 | 70.59 | 94.44 |
Ancillary tasks included those tasks where the potential harm resulting from use error would be minor in severity, or the resultant harms were estimated to occur at sufficiently low levels. Ancillary tasks included the following: wash hands; clean the injection site with alcohol swab; wait for the alcohol to dry; dispose of the autoinjector cap; inspect full dose delivered after use; dispose of the autoinjector; and treatment of injection site after injection. The percentage of participants who succesffully performed ancillary tasks during the first (Day 14) and second unassisted use (Day 28) was reported.
| percentage of participants | RA Group 1 (Self-Administration) | Caregivers | Healthcare Professionals |
|---|---|---|---|
| Day (D) 14, wash hands | 82.35 | 82.35 | 77.78 |
| D28, wash hands | 88.89 | 94.12 | 100.00 |
| D14, clean/swab injection site | 100.00 | 100.00 | 100.00 |
| D28, clean/swab injection site | 94.44 | 100.00 | 100.00 |
| D14, wait for alcohol to dry | 94.12 | 94.12 | 88.89 |
| D28, wait for alcohol to dry | 82.35 | 100.00 | 83.33 |
| D14, dispose of device cap | 94.12 | 86.67 | 83.33 |
| D28, dispose of device cap | 94.44 | 88.24 | 94.44 |
| D14, inspect full dose delivered | 100.00 | 100.00 | 100.00 |
| D28, inspect full dose delivered | 94.44 | 94.12 | 100.00 |
| D14, dispose of device | 93.33 | 100.00 | 100.00 |
| D28, dispose of device | 94.44 | 94.12 | 100.00 |
| D14, treatment of site post injection | 100.00 | 100.00 | 100.00 |
| D28, treatment of site post injection | 100.00 | 100.00 | 100.00 |
Injection pain was assessed on a continuous 100-millimeter (mm) VAS, where 0 mm represents "no pain" and 100 mm represents "unbearable pain". The mean VAS response at each assessment timepoint was reported among participants with RA.
| mm | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|
| D0, 0 minutes (min) | 2.8 ± 4.0 | 9.9 ± 13.7 | 13.3 ± 22.9 |
| D0, 15min | 1.2 ± 2.3 | 0.9 ± 1.9 | 0.8 ± 1.9 |
| D14, 0min | 5.4 ± 12.9 | 5.0 ± 7.0 | 11.4 ± 17.3 |
| D14, 15min | 1.5 ± 2.8 | 0.5 ± 0.9 | 0.7 ± 1.4 |
| D28, 0min | 4.5 ± 5.2 | 5.8 ± 9.0 | 14.5 ± 20.1 |
| D28, 15min | 0.6 ± 1.5 | 1.9 ± 5.7 | 0.7 ± 1.2 |
Injection pain was assessed on a categorical 6-point Likert scale, ranging from "no pain" to "severe and intolerable". The percentage of participants was reported by response at each assessment timepoint among participants with RA.
| percentage of participants | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|
| D0, 0min, no pain | 66.7 | 47.1 | 47.4 |
| D0, 0min, minimal but tolerable | 33.3 | 41.2 | 21.1 |
| D0, 0min, mild but tolerable | 0 | 11.8 | 21.1 |
| D0, 0min, moderate but tolerable | 0 | 0 | 5.3 |
| D0, 0min, moderate-severe/tolerable | 0 | 0 | 5.3 |
| D0, 0min, severe and intolerable | 0 | 0 | 0 |
| D0, 15min, no pain | 88.9 | 100.0 | 94.7 |
| D0, 15min, minimal but tolerable | 11.1 | 0 | 5.3 |
| D0, 15min, mild but tolerable | 0 | 0 | 0 |
| D0, 15min, moderate but tolerable | 0 | 0 | 0 |
| D0, 15min, moderate-severe/tolerable | 0 | 0 | 0 |
| D0, 15min, severe and intolerable | 0 | 0 | 0 |
| D14, 0min, no pain | 70.6 | 64.7 | 52.9 |
| D14, 0min, minimal but tolerable | 23.5 | 35.3 | 17.6 |
| D14, 0min, mild but tolerable | 5.9 | 0 | 11.8 |
| D14, 0min, moderate but tolerable | 0 | 0 | 5.9 |
| D14, 0min, moderate-severe/tolerable | 0 | 0 | 11.8 |
| D14, 0min, severe and intolerable | 0 | 0 | 0 |
| D14, 15min, no pain | 88.2 | 100.0 | 82.4 |
| D14, 15min, minimal but tolerable | 11.8 | 0 | 17.6 |
| D14, 15min, mild but tolerable | 0 | 0 | 0 |
| D14, 15min, moderate but tolerable | 0 | 0 | 0 |
| D14, 15min, moderate-severe/tolerable | 0 | 0 | 0 |
| D14, 15min, severe and intolerable | 0 | 0 | 0 |
| D28, 0min, no pain | 72.2 | 68.8 | 55.6 |
| D28, 0min, minimal but tolerable | 27.8 | 18.8 | 33.3 |
| D28, 0min, mild but tolerable | 0 | 12.5 | 5.6 |
| D28, 0min, moderate but tolerable | 0 | 0 | 5.6 |
| D28, 0min, moderate-severe/tolerable | 0 | 0 | 0 |
| D28, 0min, severe and intolerable | 0 | 0 | 0 |
| D28, 15min, no pain | 100.0 | 100.0 | 88.9 |
| D28, 15min, minimal but tolerable | 0 | 0 | 11.1 |
| D28, 15min, mild but tolerable | 0 | 0 | 0 |
| D28, 15min, moderate but tolerable | 0 | 0 | 0 |
| D28, 15min, moderate-severe/tolerable | 0 | 0 | 0 |
| D28, 15min, severe and intolerable | 0 | 0 | 0 |
Device satisfaction was assessed using twelve questions on a categorical 5-point Likert scale, ranging from "strongly agree" to "strongly disagree". Question (Q) 1 (felt the autoinjection was easy to use), Q2 (felt comfortable while using the autoinjector), Q3 (felt the autoinjector was easy to hold), Q4 (able to tell when injection had completed), Q5 (felt he/she can inject properly with the autoinjector), Q6 (felt he/she had control over the injection process), Q7 (felt confident that he/she injected successfully), Q8 (felt it is easy to dispose of the autoinjector), Q9 (autoinjector would help to manage his/her injection schedule), Q10 (liked the look/feel of the autoinjector), Q11 (would recommend the autoinjector to someone else who needed to inject), Q12 (would continue having injections with the autoinjector). The percentage of participants was reported by response at each assessment among participants with RA, CGs, and HCPs.
| percentage of participants | RA Group 1 (Self-Administration) | Caregivers | Healthcare Professionals | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|---|---|
| Q1, D0, strongly disagree | 0 | 0 | — | — | — |
| Q1, D0, disagree | 0 | 0 | — | — | — |
| Q1, D0, neutral | 5.6 | 5.9 | — | — | — |
| Q1, D0, agree | 11.1 | 0 | — | — | — |
| Q1, D0, strongly agree | 83.3 | 94.1 | — | — | — |
| Q1, D14, strongly disagree | 11.8 | 6.3 | 0 | — | — |
| Q1, D14, disagree | 0 | 0 | 0 | — | — |
| Q1, D14, neutral | 0 | 0 | 5.3 | — | — |
| Q1, D14, agree | 11.8 | 12.5 | 36.8 | — | — |
| Q1, D14, strongly agree | 76.5 | 81.3 | 57.9 | — | — |
| Q1, D28, strongly disagree | 0 | 0 | 0 | — | — |
| Q1, D28, disagree | 0 | 11.8 | 0 | — | — |
| Q1, D28, neutral | 0 | 0 | 0 | — | — |
| Q1, D28, agree | 16.7 | 11.8 | 27.8 | — | — |
| Q1, D28, strongly agree | 83.3 | 76.5 | 72.2 | — | — |
| Q2, D0, strongly disagree | 0 | 0 | — | — | — |
| Q2, D0, disagree | 0 | 5.9 | — | — | — |
| Q2, D0, neutral | 0 | 0 | — | — | — |
| Q2, D0, agree | 22.2 | 11.8 | — | — | — |
| Q2, D0, strongly agree | 77.8 | 82.4 | — | — | — |
| Q2, D14, strongly disagree | 5.9 | 0 | 0 | — | — |
| Q2, D14, disagree | 0 | 6.3 | 0 | — | — |
| Q2, D14, neutral | 0 | 0 | 0 | — | — |
| Q2, D14, agree | 23.5 | 12.5 | 42.1 | — | — |
| Q2, D14, strongly agree | 70.6 | 81.3 | 57.9 | — | — |
| Q2, D28, strongly disagree | 0 | 0 | 0 | — | — |
| Q2, D28, disagree | 0 | 11.8 | 0 | — | — |
| Q2, D28, neutral | 0 | 0 | 0 | — | — |
| Q2, D28, agree | 16.7 | 11.8 | 27.8 | — | — |
| Q2, D28, strongly agree | 83.3 | 76.5 | 72.2 | — | — |
| Q3, D0, strongly disagree | 0 | 0 | — | — | — |
| Q3, D0, disagree | 5.6 | 0 | — | — | — |
| Q3, D0, neutral | 5.6 | 5.9 | — | — | — |
| Q3, D0, agree | 27.8 | 5.9 | — | — | — |
| Q3, D0, strongly agree | 61.1 | 88.2 | — | — | — |
| Q3, D14, strongly disagree | 5.9 | 0 | 0 | — | — |
| Q3, D14, disagree | 5.9 | 6.3 | 0 | — | — |
| Q3, D14, neutral | 0 | 6.3 | 0 | — | — |
| Q3, D14, agree | 17.6 | 18.8 | 31.6 | — | — |
| Q3, D14, strongly agree | 70.6 | 68.8 | 68.4 | — | — |
| Q3, D28, strongly disagree | 0 | 0 | 0 | — | — |
| Q3, D28, disagree | 0 | 5.9 | 0 | — | — |
| Q3, D28, neutral | 0 | 0 | 0 | — | — |
| Q3, D28, agree | 16.7 | 11.8 | 22.2 | — | — |
| Q3, D28, strongly agree | 83.3 | 82.4 | 77.8 | — | — |
| Q4, D0, strongly disagree | 0 | 0 | — | — | — |
| Q4, D0, disagree | 11.1 | 5.9 | — | — | — |
| Q4, D0, neutral | 0 | 5.9 | — | — | — |
| Q4, D0, agree | 44.4 | 17.6 | — | — | — |
| Q4, D0, strongly agree | 44.4 | 70.6 | — | — | — |
| Q4, D14, strongly disagree | 5.9 | 0 | 0 | — | — |
| Q4, D14, disagree | 5.9 | 6.7 | 0 | — | — |
| Q4, D14, neutral | 11.8 | 0 | 0 | — | — |
| Q4, D14, agree | 17.6 | 13.3 | 31.6 | — | — |
| Q4, D14, strongly agree | 58.8 | 80.0 | 68.4 | — | — |
| Q4, D28, strongly disagree | 0 | 5.9 | 0 | — | — |
| Q4, D28, disagree | 0 | 0 | 0 | — | — |
| Q4, D28, neutral | 0 | 0 | 0 | — | — |
| Q4, D28, agree | 22.2 | 11.8 | 16.7 | — | — |
| Q4, D28, strongly agree | 77.8 | 82.4 | 83.3 | — | — |
| Q5, D0, strongly disagree | 0 | 0 | — | — | — |
| Q5, D0, disagree | 0 | 0 | — | — | — |
| Q5, D0, neutral | 11.1 | 0 | — | — | — |
| Q5, D0, agree | 22.2 | 11.8 | — | — | — |
| Q5, D0, strongly agree | 66.7 | 88.2 | — | — | — |
| Q5, D14, strongly disagree | 5.9 | 0 | 0 | — | — |
| Q5, D14, disagree | 0 | 6.3 | 0 | — | — |
| Q5, D14, neutral | 5.9 | 6.3 | 0 | — | — |
| Q5, D14, agree | 11.8 | 0 | 15.8 | — | — |
| Q5, D14, strongly agree | 76.5 | 87.5 | 84.2 | — | — |
| Q5, D28, strongly disagree | 0 | 0 | 0 | — | — |
| Q5, D28, disagree | 0 | 5.9 | 0 | — | — |
| Q5, D28, neutral | 0 | 0 | 0 | — | — |
| Q5, D28, agree | 16.7 | 11.8 | 22.2 | — | — |
| Q5, D28, strongly agree | 83.3 | 82.4 | 77.8 | — | — |
| Q6, D0, strongly disagree | 0 | 0 | — | — | — |
| Q6, D0, disagree | 5.6 | 0 | — | — | — |
| Q6, D0, neutral | 5.6 | 5.9 | — | — | — |
| Q6, D0, agree | 16.7 | 5.9 | — | — | — |
| Q6, D0, strongly agree | 72.2 | 88.2 | — | — | — |
| Q6, D14, strongly disagree | 5.9 | 0 | 0 | — | — |
| Q6, D14, disagree | 5.9 | 6.3 | 0 | — | — |
| Q6, D14, neutral | 0 | 6.3 | 0 | — | — |
| Q6, D14, agree | 11.8 | 12.5 | 26.3 | — | — |
| Q6, D14, strongly agree | 76.5 | 75.0 | 73.7 | — | — |
| Q6, D28, strongly disagree | 0 | 0 | 0 | — | — |
| Q6, D28, disagree | 0 | 0 | 0 | — | — |
| Q6, D28, neutral | 0 | 5.9 | 0 | — | — |
| Q6, D28, agree | 16.7 | 11.8 | 22.2 | — | — |
| Q6, D28, strongly agree | 83.3 | 82.4 | 77.8 | — | — |
| Q7, D0, strongly disagree | 0 | 0 | — | — | — |
| Q7, D0, disagree | 11.1 | 5.9 | — | — | — |
| Q7, D0, neutral | 0 | 0 | — | — | — |
| Q7, D0, agree | 16.7 | 17.6 | — | — | — |
| Q7, D0, strongly agree | 72.2 | 76.5 | — | — | — |
| Q7, D14, strongly disagree | 5.9 | 0 | 0 | — | — |
| Q7, D14, disagree | 0 | 0 | 0 | — | — |
| Q7, D14, neutral | 5.9 | 0 | 0 | — | — |
| Q7, D14, agree | 17.6 | 6.7 | 21.1 | — | — |
| Q7, D14, strongly agree | 70.6 | 93.3 | 78.9 | — | — |
| Q7, D28, strongly disagree | 0 | 5.9 | 0 | — | — |
| Q7, D28, disagree | 0 | 0 | 0 | — | — |
| Q7, D28, neutral | 0 | 0 | 0 | — | — |
| Q7, D28, agree | 16.7 | 11.8 | 11.1 | — | — |
| Q7, D28, strongly agree | 83.3 | 82.4 | 88.9 | — | — |
| Q8, D0, strongly disagree | 0 | 0 | — | — | — |
| Q8, D0, disagree | 0 | 0 | — | — | — |
| Q8, D0, neutral | 0 | 0 | — | — | — |
| Q8, D0, agree | 16.7 | 5.9 | — | — | — |
| Q8, D0, strongly agree | 83.3 | 94.1 | — | — | — |
| Q8, D14, strongly disagree | 0 | 0 | 0 | — | — |
| Q8, D14, disagree | 5.9 | 0 | 0 | — | — |
| Q8, D14, neutral | 0 | 0 | 0 | — | — |
| Q8, D14, agree | 17.6 | 0 | 10.5 | — | — |
| Q8, D14, strongly agree | 76.5 | 100.0 | 89.5 | — | — |
| Q8, D28, strongly disagree | 0 | 0 | 0 | — | — |
| Q8, D28, disagree | 0 | 5.9 | 0 | — | — |
| Q8, D28, neutral | 0 | 0 | 0 | — | — |
| Q8, D28, agree | 16.7 | 11.8 | 11.1 | — | — |
| Q8, D28, strongly agree | 83.3 | 82.4 | 88.9 | — | — |
| Q9, D0, strongly disagree | 0 | — | — | 7.1 | 0 |
| Q9, D0, disagree | 0 | — | — | 0 | 0 |
| Q9, D0, neutral | 5.6 | — | — | 7.1 | 17.6 |
| Q9, D0, agree | 38.9 | — | — | 28.6 | 29.4 |
| Q9, D0, strongly agree | 55.6 | — | — | 57.1 | 52.9 |
| Q9, D14, strongly disagree | 0 | — | — | 0 | 0 |
| Q9, D14, disagree (n=17,0,0,16,17) | 0 | — | — | 0 | 0 |
| Q9, D14, neutral | 5.9 | — | — | 12.5 | 23.5 |
| Q9, D14, agree | 35.3 | — | — | 18.8 | 23.5 |
| Q9, D14, strongly agree | 58.8 | — | — | 68.8 | 52.9 |
| Q9, D28, strongly disagree | 0 | — | — | 0 | 5.6 |
| Q9, D28, disagree | 0 | — | — | 0 | 0 |
| Q9, D28, neutral | 0 | — | — | 12.5 | 16.7 |
| Q9, D28, agree | 27.8 | — | — | 18.8 | 33.3 |
| Q9, D28, strongly agree | 72.2 | — | — | 68.8 | 44.4 |
| Q10, D0, strongly disagree | 0 | 0 | — | 7.1 | 0 |
| Q10, D0, disagree | 0 | 0 | — | 0 | 0 |
| Q10, D0, neutral | 11.1 | 11.8 | — | 7.1 | 11.8 |
| Q10, D0, agree | 33.3 | 11.8 | — | 21.4 | 41.2 |
| Q10, D0, strongly agree | 55.6 | 76.5 | — | 64.3 | 47.1 |
| Q10, D14, strongly disagree | 5.9 | 0 | 0 | 0 | 0 |
| Q10, D14, disagree | 5.9 | 0 | 0 | 6.3 | 5.9 |
| Q10, D14, neutral | 0 | 0 | 0 | 6.3 | 11.8 |
| Q10, D14, agree | 23.5 | 43.8 | 31.6 | 12.5 | 41.2 |
| Q10, D14, strongly agree | 64.7 | 56.3 | 68.4 | 75.0 | 41.2 |
| Q10, D28, strongly disagree | 0 | 5.9 | 0 | 0 | 0 |
| Q10, D28, disagree | 0 | 0 | 0 | 0 | 5.6 |
| Q10, D28, neutral | 11.1 | 0 | 5.6 | 12.5 | 0 |
| Q10, D28, agree | 16.7 | 35.3 | 27.8 | 18.8 | 44.4 |
| Q10, D28, strongly agree | 72.2 | 58.8 | 66.7 | 68.8 | 50.0 |
| Q11, D0, strongly disagree | 0 | 0 | — | 14.3 | 0 |
| Q11, D0, disagree | 0 | 0 | — | 0 | 0 |
| Q11, D0, neutral | 0 | 5.9 | — | 7.1 | 5.9 |
| Q11, D0, agree | 27.8 | 5.9 | — | 21.4 | 35.3 |
| Q11, D0, strongly agree | 72.2 | 88.2 | — | 57.1 | 58.8 |
| Q11, D14, strongly disagree | 5.9 | 0 | 0 | 0 | 0 |
| Q11, D14, disagree | 5.9 | 6.3 | 0 | 0 | 0 |
| Q11, D14, neutral | 0 | 0 | 0 | 6.3 | 11.8 |
| Q11, D14, agree | 11.8 | 18.8 | 21.1 | 12.5 | 35.3 |
| Q11, D14, strongly agree | 76.5 | 75.0 | 78.9 | 81.3 | 52.9 |
| Q11, D28, strongly disagree | 0 | 5.9 | 0 | 0 | 0 |
| Q11, D28, disagree | 0 | 5.9 | 0 | 0 | 5.6 |
| Q11, D28, neutral | 0 | 0 | 0 | 12.5 | 5.6 |
| Q11, D28, agree | 16.7 | 5.9 | 33.3 | 6.3 | 33.3 |
| Q11, D28, strongly agree | 83.3 | 82.4 | 66.7 | 81.3 | 55.6 |
| Q12, D0, strongly disagree | 0 | — | — | 14.3 | 0 |
| Q12, D0, disagree | 0 | — | — | 0 | 0 |
| Q12, D0, neutral | 5.6 | — | — | 0 | 5.9 |
| Q12, D0, agree | 27.8 | — | — | 21.4 | 35.3 |
| Q12, D0, strongly agree | 66.7 | — | — | 64.3 | 58.8 |
| Q12, D14, strongly disagree | 5.9 | — | — | 0 | 0 |
| Q12, D14, disagree | 5.9 | — | — | 0 | 5.9 |
| Q12, D14, neutral | 0 | — | — | 6.3 | 5.9 |
| Q12, D14, agree | 5.9 | — | — | 12.5 | 35.3 |
| Q12, D14, strongly agree | 82.4 | — | — | 81.3 | 52.9 |
| Q12, D28, strongly disagree | 0 | — | — | 0 | 0 |
| Q12, D28, disagree | 0 | — | — | 6.3 | 5.6 |
| Q12, D28, neutral | 5.6 | — | — | 0 | 5.6 |
| Q12, D28, agree | 11.1 | — | — | 25.0 | 33.3 |
| Q12, D28, strongly agree | 83.3 | — | — | 68.8 | 55.6 |
Sixty-eight joints were assessed for tenderness among participants with RA. The number of tender joints at Baseline was reported.
| tender joints | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|
| Tender Joint Count (TJC) Among Participants With RA | 11.17 ± 9.32 | 8.12 ± 11.29 | 16.32 ± 16.17 |
Sixty-six joints were assessed for swelling among participants with RA. The number of swollen joints at Baseline was reported.
| swollen joints | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|
| Swollen Joint Count (SJC) Among Participants With RA | 4.61 ± 4.10 | 3.71 ± 4.45 | 8.89 ± 7.88 |
Ability to perform daily living activities was assessed across eight component sets including dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Twenty questions were scored on a 4-point Likert scale from 0 meaning "without any difficulty" to 3 meaning "unable to do". The overall score was computed as the sum of domain scores divided by the number of domains answered. Therefore, the score range for HAQ-DI was the same as that of the individual questions, that is, from 0 to 3, where 0 indicates "least difficulty" and 3 indicates "extreme difficulty". The mean change from baseline in HAQ-DI at each assessment was reported among participants with RA.
| units on a scale | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|
| D0 | 0.7222 ± 0.6974 | 0.8676 ± 0.6532 | 1.2434 ± 0.6541 |
| Change at D14 | 0.0962 ± 0.2166 | -0.0368 ± 0.1863 | -0.0441 ± 0.2575 |
| Change at D28 | 0.0139 ± 0.2674 | -0.0078 ± 0.2519 | -0.0903 ± 0.3398 |
Collected over Days 0-28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RA Group 1 (Self-Administration) | — | 0/18 (0%) | 4/18 (22.2%) |
| RA Group 2 (Administration by CG) | — | 0/17 (0%) | 4/17 (23.5%) |
| RA Group 3 (Administration by HCP) | — | 0/19 (0%) | 3/19 (15.8%) |
| Event | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) |
|---|---|---|---|
| Arthropod biteInjury, poisoning and procedural complications | 0/18 | 0/17 | 2/19 |
| StomatitisGastrointestinal disorders | 0/18 | 1/17 | 0/19 |
| Injection site pruritusGeneral disorders | 0/18 | 1/17 | 0/19 |
| Upper respiratory tract infectionInfections and infestations | 0/18 | 1/17 | 0/19 |
| DizzinessNervous system disorders | 0/18 | 1/17 | 0/19 |
| Abdominal painGastrointestinal disorders | 1/18 | 0/17 | 0/19 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 0/17 | 0/19 |
| VomitingGastrointestinal disorders | 1/18 | 0/17 | 0/19 |
| Injection site bruisingGeneral disorders | 1/18 | 0/17 | 0/19 |
| HypersensitivityImmune system disorders | 1/18 | 0/17 | 0/19 |
Safety Population: All participants who received (or in the case of CGs and HCPs, administered) at least one dose of study drug.
| Age, Categorical(Participants) | Caregivers | Healthcare Professionals | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 17 | 14 | 15 | 16 | 77 |
| >=65 years | 2 | 2 | 4 | 2 | 3 | 13 |
| Sex: Female, Male(Participants) | Caregivers | Healthcare Professionals | RA Group 1 (Self-Administration) | RA Group 2 (Administration by CG) | RA Group 3 (Administration by HCP) | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 17 | 13 | 13 | 13 | 68 |
| Male | 5 | 2 | 5 | 4 | 6 | 22 |
Ran from Mar 2016 to primary completion in Jul 2016, 4 months.
Results were first posted in Apr 2019, 2 years 8 months after primary completion. A results delay was requested in Jul 2017.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 4 months is below that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab